Summit Therapeutics PLC  

(Public, LON:SUMM)   Watch this stock  
Find more results for SUMM
-7.25 (-5.35%)
Nov 26 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 128.25 - 133.50
52 week 106.00 - 188.00
Open 135.50
Vol / Avg. 24,188.00/26,527.00
Mkt cap 79.49M*
P/E     -
Div/yield     -
EPS -0.26*
Shares 61.29M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Jul '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -45.63% -85.14%
Return on average equity -50.48% -115.20%
Employees 23 -
CDP Score - -


85B Park Drive
United Kingdom - Map
+44-1235-443939 (Phone)
+44-1235-436237 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company's lead DMD product candidate is SMT C1100, an orally administered small molecule. The Company's lead CDI product candidate is SMT19969, an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics, Inc., Summit (Oxford) Limited, Summit (Wales) Limited and MuOx Limited, among others.

Officers and directors

Glyn Edwards Chief Executive Officer, Executive Director
Age: 59
Erik Ostrowski Chief Financial Officer
Age: 42
Ralf H. Rosskamp M.D. Chief Medical Officer
Age: 61
Frank Murdoch Armstrong Non-Executive Chairman of the Board
Age: 58
Valerie L. Andrews Non-Executive Director
Age: 55
Stephen J. Davies Non-Executive Director
Age: 64
Barry J. Price Ph.D. Non-Executive Director
Age: 71
David M. Wurzer CPA Non-Executive Director
Age: 56